These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 16281441)

  • 21. Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.
    Coffie PA; Ekouevi DK; Chaix ML; Tonwe-Gold B; Clarisse AB; Becquet R; Viho I; N'dri-Yoman T; Leroy V; Abrams EJ; Rouzioux C; Dabis F
    Clin Infect Dis; 2008 Feb; 46(4):611-21. PubMed ID: 18197758
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Primary HIV-1 infection--a "window of opportunity" for healthcare providers.
    Maniar AJ; Maniar JK; Kamath R; Shah S; Verma R; Kinloch S
    J Assoc Physicians India; 2008 Aug; 56():628-32. PubMed ID: 19051710
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Potential impact of early antiretroviral therapy on transmission.
    Pao D; Pillay D; Fisher M
    Curr Opin HIV AIDS; 2009 May; 4(3):215-21. PubMed ID: 19532053
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antiretroviral management of treatment-naive patients.
    Gulick RM
    Infect Dis Clin North Am; 2007 Mar; 21(1):71-84, viii. PubMed ID: 17502230
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Managing antiretroviral therapy: changing regimens, resistance testing, and the risks from structured treatment interruptions.
    Eron JJ
    J Infect Dis; 2008 May; 197 Suppl 3():S261-71. PubMed ID: 18447612
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Persistent humoral immune defect in highly active antiretroviral therapy-treated children with HIV-1 infection: loss of specific antibodies against attenuated vaccine strains and natural viral infection.
    Bekker V; Scherpbier H; Pajkrt D; Jurriaans S; Zaaijer H; Kuijpers TW
    Pediatrics; 2006 Aug; 118(2):e315-22. PubMed ID: 16847077
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis.
    Attia S; Egger M; Müller M; Zwahlen M; Low N
    AIDS; 2009 Jul; 23(11):1397-404. PubMed ID: 19381076
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HIV/AIDS: the management of treatment-experienced HIV-infected patients: new drugs and drug combinations.
    Wilson LE; Gallant JE
    Clin Infect Dis; 2009 Jan; 48(2):214-21. PubMed ID: 19072245
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Short-term antiviral activity of TMC278--a novel NNRTI--in treatment-naive HIV-1-infected subjects.
    Goebel F; Yakovlev A; Pozniak AL; Vinogradova E; Boogaerts G; Hoetelmans R; de Béthune MP; Peeters M; Woodfall B
    AIDS; 2006 Aug; 20(13):1721-6. PubMed ID: 16931936
    [TBL] [Abstract][Full Text] [Related]  

  • 30. AIDS in the Third World: how to stop the HIV infection?
    De Clercq E
    Verh K Acad Geneeskd Belg; 2007; 69(2):65-80. PubMed ID: 17550059
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative potency of three antiretroviral therapy regimes in primary HIV infection.
    Fidler S; Fraser C; Fox J; Tamm N; Griffin JT; Weber J
    AIDS; 2006 Jan; 20(2):247-52. PubMed ID: 16511418
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High frequency of highly active antiretroviral therapy modifications in patients with acute or early human immunodeficiency virus infection.
    Sabundayo BP; McArthur JH; Langan SJ; Gallant JE; Margolick JB
    Pharmacotherapy; 2006 May; 26(5):674-81. PubMed ID: 16637796
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Higher set point plasma viral load and more-severe acute HIV type 1 (HIV-1) illness predict mortality among high-risk HIV-1-infected African women.
    Lavreys L; Baeten JM; Chohan V; McClelland RS; Hassan WM; Richardson BA; Mandaliya K; Ndinya-Achola JO; Overbaugh J
    Clin Infect Dis; 2006 May; 42(9):1333-9. PubMed ID: 16586394
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The incidence of and risk factors for HIV-associated cognitive-motor complex among patients on HAART.
    Jevtović Dj; Vanovac V; Veselinović M; Salemović D; Ranin J; Stefanova E
    Biomed Pharmacother; 2009 Sep; 63(8):561-5. PubMed ID: 19026516
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment interruptions in HIV-infected subjects.
    Bongiovanni M; Casana M; Tincati C; d'Arminio Monforte A
    J Antimicrob Chemother; 2006 Sep; 58(3):502-5. PubMed ID: 16816398
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-Term suppression of HIV infection: benefits and limitations of current treatment options.
    Sension MG
    J Assoc Nurses AIDS Care; 2007; 18(1 Suppl):S2-10. PubMed ID: 17275719
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Early identification of seronegative human immunodeficiency virus type 1 infection with severe presentation.
    Chin BS; Lee SH; Kim GJ; Kee MK; Suh SD; Kim SS
    J Clin Microbiol; 2007 May; 45(5):1659-62. PubMed ID: 17344360
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Acute HIV infection].
    Machala L; Cerný R
    Cas Lek Cesk; 2004; 143(9):584-7; discussion 587-8. PubMed ID: 15532895
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structured treatment interruptions--new findings.
    Benson CA
    Top HIV Med; 2006; 14(3):107-11. PubMed ID: 16946455
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [A case of primary HIV infection presenting as mononeuritis multiplex].
    Sugimoto H; Konno S; Takamiya K; Nemoto H; Wakata N; Kurihara T
    Rinsho Shinkeigaku; 2006 Aug; 46(8):561-3. PubMed ID: 17154036
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.